Alnylam [ALNY] vs Vertex [VRTX] Detailed Stock Comparison
Alnylam
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Alnylam wins in 6 metrics, Vertex wins in 12 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alnylam | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -209.81 | 27.47 | Alnylam |
| Price-to-Book Ratio | 236.81 | 5.90 | Vertex |
| Debt-to-Equity Ratio | 1,093.31 | 8.89 | Vertex |
| PEG Ratio | -0.72 | -0.21 | Alnylam |
| EV/EBITDA | -487.23 | 20.10 | Alnylam |
| Profit Margin (TTM) | -12.96% | 31.86% | Vertex |
| Operating Margin (TTM) | -2.09% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -257.83% | 22.77% | Vertex |
| Return on Assets (TTM) | -2.63% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-42.59M | $-978.00M | Alnylam |
| 1-Year Return | 72.02% | -10.20% | Alnylam |
| Price-to-Sales Ratio (TTM) | 24.12 | 8.88 | Vertex |
| Enterprise Value | $60.26B | $96.50B | Vertex |
| EV/Revenue Ratio | 24.48 | 8.45 | Vertex |
| Gross Profit Margin (TTM) | 81.52% | 86.25% | Vertex |
| Revenue per Share (TTM) | $19 | $44 | Vertex |
| Earnings per Share (Diluted) | $-2.49 | $14.39 | Vertex |
| Beta (Stock Volatility) | 0.35 | 0.44 | Alnylam |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Alnylam vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alnylam | 0.07% | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% |
| Vertex | 1.15% | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alnylam | 72.02% | 135.43% | 213.60% | 454.34% | 3,521.29% | 4,415.08% |
| Vertex | -10.20% | 38.49% | 51.45% | 271.68% | 1,057.89% | 1,798.98% |
News Based Sentiment: Alnylam vs Vertex
Alnylam
News based Sentiment: POSITIVE
October proved to be a strong month for Alnylam, highlighted by a significant milestone payment triggered by the start of a key Phase 3 trial and consistent analyst reports indicating the stock is significantly undervalued. These factors, combined with portfolio diversification efforts, create a positive outlook for the company.
Vertex
News based Sentiment: POSITIVE
Vertex Pharmaceuticals delivered strong financial results in Q2 2025 and raised its full-year guidance, coupled with positive developments in its pipeline and favorable analyst coverage. This combination of factors indicates a positive trajectory for the company and strengthens the investment case.
Performance & Financial Health Analysis: Alnylam vs Vertex
| Metric | ALNY | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $60.43B | $100.41B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 969,587 | 2,025,380 |
| 90 Day Avg. Volume | 1,063,879 | 1,632,117 |
| Last Close | $460.99 | $408.85 |
| 52 Week Range | $205.87 - $484.21 | $362.50 - $519.88 |
| % from 52W High | -4.80% | -21.36% |
| All-Time High | $484.21 (Sep 09, 2025) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -4.80% | -21.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.12% |
| Quarterly Earnings Growth | 0.17% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | 0.32% |
| Operating Margin (TTM) | -0.02% | 0.39% |
| Return on Equity (TTM) | -2.58% | 0.23% |
| Debt to Equity (MRQ) | 1,093.31 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.91 | $67.02 |
| Cash per Share (MRQ) | $21.80 | $24.90 |
| Operating Cash Flow (TTM) | $-15,539,000 | $3.85B |
| Levered Free Cash Flow (TTM) | $85.71M | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Alnylam vs Vertex
| Metric | ALNY | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -209.81 | 27.47 |
| Forward P/E | -371.32 | 21.06 |
| PEG Ratio | -0.72 | -0.21 |
| Price to Sales (TTM) | 24.12 | 8.88 |
| Price to Book (MRQ) | 236.81 | 5.90 |
| Market Capitalization | ||
| Market Capitalization | $60.43B | $100.41B |
| Enterprise Value | $60.26B | $96.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 24.48 | 8.45 |
| Enterprise to EBITDA | -487.23 | 20.10 |
| Risk & Other Metrics | ||
| Beta | 0.35 | 0.44 |
| Book Value per Share (MRQ) | $1.91 | $67.02 |
Financial Statements Comparison: Alnylam vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ALNY | VRTX |
|---|---|---|
| Revenue/Sales | $773.69M | $2.96B |
| Cost of Goods Sold | $142.95M | $407.50M |
| Gross Profit | $630.74M | $2.56B |
| Research & Development | $323.62M | $978.40M |
| Operating Income (EBIT) | $-16.20M | $1.15B |
| EBITDA | $35.44M | $1.34B |
| Pre-Tax Income | $-35.36M | $1.28B |
| Income Tax | $30.92M | $250.10M |
| Net Income (Profit) | $-66.28M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ALNY | VRTX |
|---|---|---|
| Cash & Equivalents | $1.02B | $4.67B |
| Total Current Assets | $3.27B | $10.01B |
| Total Current Liabilities | $1.08B | $3.78B |
| Long-Term Debt | $1.26B | $1.65B |
| Total Shareholders Equity | $115.44M | $16.50B |
| Retained Earnings | $-7.35B | $10.25B |
| Property, Plant & Equipment | $695.92M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ALNY | VRTX |
|---|---|---|
| Operating Cash Flow | $-145.39M | $404.90M |
| Capital Expenditures | $-8.97M | $-40.70M |
| Free Cash Flow | $-127.28M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | ALNY | VRTX |
|---|---|---|
| Shares Short | 3.72M | 4.05M |
| Short Ratio | 3.28 | 2.83 |
| Short % of Float | 0.04% | 0.02% |
| Average Daily Volume (10 Day) | 969,587 | 2,025,380 |
| Average Daily Volume (90 Day) | 1,063,879 | 1,632,117 |
| Shares Outstanding | 129.29M | 256.94M |
| Float Shares | 126.15M | 255.58M |
| % Held by Insiders | 0.04% | 0.00% |
| % Held by Institutions | 0.99% | 0.98% |
Dividend Analysis & Yield Comparison: Alnylam vs Vertex
| Metric | ALNY | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |